Stock Split History
ETFs Holding ARCT »    ARCT Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Arcturus Therapeutics Holdings is a global clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and other opportunities within liver and respiratory rare diseases. Co.'s coronavirus disease 2019 vaccine candidate, ARCT-021, is designed to promote immune responses to the spike protein of the Severe Acute Respiratory Syndrome-2 virus, which is the part of the virus that allows infection to occur. The LUNAR-OTC development program addresses ornithine transcarbamylase (OTC) deficiency, a genetic disease caused by mutations in the OTC gene that lead to dysfunctional or deficient OTC. The LUNAR-CF program addresses cystic fibrosis lung disease. According to our Arcturus Therapeutics Holdings stock split history records, Arcturus Therapeutics Holdings has had 1 split.
Arcturus Therapeutics Holdings stock split history picture
Arcturus Therapeutics Holdings (ARCT) has 1 split in our Arcturus Therapeutics Holdings stock split history database. The split for ARCT took place on November 16, 2017. This was a 1 for 7 reverse split, meaning for each 7 shares of ARCT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split.

When a company such as Arcturus Therapeutics Holdings conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the Arcturus Therapeutics Holdings stock split history from start to finish, an original position size of 1000 shares would have turned into 142.857142857143 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arcturus Therapeutics Holdings shares, starting with a $10,000 purchase of ARCT, presented on a split-history-adjusted basis factoring in the complete Arcturus Therapeutics Holdings stock split history. Arcturus Therapeutics Holdings split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/23/2013
End date: 09/23/2022
Start price/share: $50.47
End price/share: $13.62
Dividends collected/share: $0.00
Total return: -73.01%
Average Annual Total Return: -13.08%
Starting investment: $10,000.00
Ending investment: $2,699.16
Years: 9.34
Date Ratio
11/16/20171 for 7
Annaly Capital Management, Inc. (NLY)
CohBar, Inc. (CWBR)
TOP Ships Inc. (TOPS)
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Nabriva Therapeutics plc (NBRV)
NeuroBo Pharmaceuticals, Inc. (NRBO)
First Wave BioPharma, Inc. (FWBI)
Palatin Technologies, Inc. (PTIN)
TD Holdings, Inc. (GLG )
Iterum Therapeutics plc (ITRM)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »
Funds Holding Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Insider Buying

Arcturus Therapeutics Holdings Stock Split History | www.StockSplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.StockSplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.